NFE2L2 and ovarian cancer: Further evidence to implicate NRF2 in the regulation of HER1 expression was obtained when cotreatment of the ovarian cancer and MCF7 AREc32 cells with tBHQ and NRF2-siRNA compromised the tBHQ-dependent induction of either HER1 promoter-driven or ARE-driven luciferase gene expression in the ovarian cancer cells or in MCF7 AREc32 cells (Figure 4(a)), respectively.